Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

UroGen Pharma (URGN) Net Margin (2017 - 2025)

UroGen Pharma's Net Margin history spans 9 years, with the latest figure at 69.68% for Q4 2025.

  • For Q4 2025, Net Margin rose 8303.0% year-over-year to 69.68%; the TTM value through Dec 2025 reached 139.81%, up 54.0%, while the annual FY2025 figure was 139.81%, 54.0% up from the prior year.
  • Net Margin reached 69.68% in Q4 2025 per URGN's latest filing, up from 121.34% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 69.68% in Q4 2025 to a low of 346.49% in Q1 2021.
  • Average Net Margin over 5 years is 168.52%, with a median of 160.61% recorded in 2022.
  • Peak YoY movement for Net Margin: soared 822594bps in 2021, then tumbled -5335bps in 2025.
  • A 5-year view of Net Margin shows it stood at 175.91% in 2021, then rose by 9bps to 159.57% in 2022, then skyrocketed by 31bps to 110.57% in 2023, then tumbled by -38bps to 152.71% in 2024, then soared by 54bps to 69.68% in 2025.
  • Per Business Quant, the three most recent readings for URGN's Net Margin are 69.68% (Q4 2025), 121.34% (Q3 2025), and 206.24% (Q2 2025).